Jeremy Pratt

1.1k total citations
27 papers, 767 citations indexed

About

Jeremy Pratt is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, Jeremy Pratt has authored 27 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Cellular and Molecular Neuroscience and 8 papers in Neurology. Recurrent topics in Jeremy Pratt's work include Neuroscience and Neuropharmacology Research (14 papers), Ion channel regulation and function (7 papers) and Amyotrophic Lateral Sclerosis Research (5 papers). Jeremy Pratt is often cited by papers focused on Neuroscience and Neuropharmacology Research (14 papers), Ion channel regulation and function (7 papers) and Amyotrophic Lateral Sclerosis Research (5 papers). Jeremy Pratt collaborates with scholars based in France, Germany and Australia. Jeremy Pratt's co-authors include Jean‐Marie Stutzmann, Jean Rataud, Véronique Mary, Alain Boireau, Michel J. Roux, Assunta Impérato, Pierre M. Laduron, Jean‐Charles Blanchard, Thomas Boraud and Christian E. Gross and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and European Journal of Pharmacology.

In The Last Decade

Jeremy Pratt

27 papers receiving 717 citations

Peers

Jeremy Pratt
K.R. Hunter United Kingdom
Eun-Cheol Song South Korea
C. Koch United States
H. Yasuda Japan
Amy H. Moore United States
Jeremy Pratt
Citations per year, relative to Jeremy Pratt Jeremy Pratt (= 1×) peers Jean-Christophe Delumeau

Countries citing papers authored by Jeremy Pratt

Since Specialization
Citations

This map shows the geographic impact of Jeremy Pratt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Pratt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Pratt more than expected).

Fields of papers citing papers by Jeremy Pratt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Pratt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Pratt. The network helps show where Jeremy Pratt may publish in the future.

Co-authorship network of co-authors of Jeremy Pratt

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Pratt. A scholar is included among the top collaborators of Jeremy Pratt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Pratt. Jeremy Pratt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gossel, Matthias, Jeremy Pratt, Mark D. Black, et al.. (2010). Profiling of Energy Metabolism in Olanzapine‐Induced Weight Gain in Rats and Its Prevention by the CB1‐Antagonist AVE1625. Obesity. 18(10). 1952–1958. 12 indexed citations
3.
Mignani, Serge, Georg Andrees Böhme, Guillaume Birraux, et al.. (2002). 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic Acid (RPR117824): Selective Anticonvulsive and Neuroprotective AMPA Antagonist. Bioorganic & Medicinal Chemistry. 10(5). 1627–1637. 27 indexed citations
4.
Canton, Thierry, Georg Andrees Böhme, Alain Boireau, et al.. (2001). RPR 119990, a Novel α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Antagonist: Synthesis, Pharmacological Properties, and Activity in an Animal Model of Amyotrophic Lateral Sclerosis. Journal of Pharmacology and Experimental Therapeutics. 299(1). 314–322. 33 indexed citations
5.
Jimonet, Patrick, Georg Andrees Böhme, Alain Boireau, et al.. (2001). Bioisosteres of 9-Carboxymethyl-4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent In Vivo AMPA antagonists with longer durations of action. Bioorganic & Medicinal Chemistry Letters. 11(2). 127–132. 9 indexed citations
6.
Kennel, Philippe, Frédéric Revah, Georg Andrees Böhme, et al.. (2000). Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). Journal of the Neurological Sciences. 180(1-2). 55–61. 28 indexed citations
7.
Jimonet, Patrick, Georg Andrees Böhme, Alain Boireau, et al.. (2000). 8-Methylureido-10-amino-10-methyl-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-ones: Highly In vivo Potent and Selective AMPA Receptor Antagonists. Bioorganic & Medicinal Chemistry. 8(8). 2211–2217. 3 indexed citations
8.
Stutzmann, J.M., Georg Andrees Böhme, Alain Boireau, et al.. (2000). 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives. Bioorganic & Medicinal Chemistry Letters. 10(10). 1133–1137. 14 indexed citations
9.
Pratt, Jeremy, Patrick Jimonet, Georg Andrees Böhme, et al.. (2000). Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]indeno[1,2-e]pyrazin-8- and -9-carboxylic (acetic) acid AMPA antagonists. Bioorganic & Medicinal Chemistry Letters. 10(24). 2749–2754. 9 indexed citations
10.
Jimonet, Patrick, Alain Boireau, Dominique Damour, et al.. (1999). Spiro-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives are mixed AMPA and NMDA glycine-site antagonists active in vivo. Bioorganic & Medicinal Chemistry Letters. 9(20). 2921–2926. 21 indexed citations
11.
Pratt, Jeremy, Georg Andrees Böhme, Michel J. Roux, et al.. (1999). The effect of riluzole and mannitol on cerebral oedema after cryogenic injury in the mouse. Neuroscience Letters. 272(3). 143–146. 8 indexed citations
12.
Mignani, Serge, Michel Barreau, Alain Boireau, et al.. (1999). Synthesis and pharmacological properties of 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, a new competitive AMPA/KA receptor antagonist. Drug Development Research. 48(3). 121–129. 9 indexed citations
13.
Canton, Thierry, Jeremy Pratt, Jean‐Marie Stutzmann, Assunta Impérato, & Alain Boireau. (1998). Glutamate uptake is decreased tardively in the spinal cord of FALS mice. Neuroreport. 9(5). 775–778. 58 indexed citations
14.
Pratt, Jeremy, et al.. (1998). Enoxaparin Reduces Cerebral Edemaafter Photothrombotic Injury in the Rat. Pathophysiology of Haemostasis and Thrombosis. 28(2). 78–85. 17 indexed citations
15.
Stutzmann, Jean‐Marie, Jeremy Pratt, Thomas Boraud, & Christian E. Gross. (1996). The effect of riluzole on post-traumatic spinal cord injury in the rat. Neuroreport. 7(2). 387–392. 65 indexed citations
16.
Pratt, Jeremy, et al.. (1995). Acute effects of irradiation on the rat brain: protection by glutamate blockade. European Journal of Pharmacology. 276(1-2). 55–60. 16 indexed citations
17.
Jimonet, Patrick, Magalie Barreau, J.C. Blanchard, et al.. (1994). Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative. Bioorganic & Medicinal Chemistry. 2(8). 793–798. 15 indexed citations
18.
Pratt, Jeremy, et al.. (1994). Neuroprotective effects of colchicine in the gerbil model of cerebral ischaemia. Neuroscience Letters. 169(1-2). 114–118. 10 indexed citations
19.
Rataud, Jean, et al.. (1994). Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neuroscience Letters. 172(1-2). 19–23. 99 indexed citations
20.
Pratt, Jeremy, Jean Rataud, Michel J. Roux, et al.. (1992). Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neuroscience Letters. 140(2). 225–230. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026